

# OPIOID PRESCRIBING DECISION AID

Opioids are an important medicine for the management of pain. However, opioid misuse is a significant risk for anyone using opioids. Balancing the need for pain relief with harm minimisation can be challenging. Being overly suspicious of requests for opioids may leave people feeling stigmatised and prevent people getting access to medicines that may improve their quality of life.

The Tasmanian Department of Health has developed an 8-step checklist that can be used at any point during the management of patients on opioids, such as initiation, or when making decisions to increase dose, reduce therapy or manage patients showing signs of misuse or side effects from opioids.<sup>1</sup>

# 8 Cs of pr

## of prescribing opioids

Clinical indication	Are opioids suitable for this indication? Has the patient been treated with appropriate non-opioid analgesia at the correct dose prior to the decision to use opioids?
Clinical risks	Are there considerations regarding comorbidities or interaction with other medicines?
Consider signs of misuse or abuse	Is the patient displaying any signs of dependence, misuse or abuse? (Table 1) <sup>A</sup>
Control dose	Use the lowest effective dose. Avoid exceeding accepted maximum doses. <sup>B</sup>
Contract	Consider the use of an opioid contract signed by patient and prescriber. This should include treatment goals and agreement to discontinue if goals are not met. <sup>c</sup>
Contact PBS	Apply for authority as per State or Territory legislation.
Contain prescription	Single prescriber and single pharmacy prescription is recommended to prevent doctor shopping.
Consensus between parties	Regarding treatment, for example: outcomes such as function, review frequency, other treatment strategies and discontinuation plan.

- A The use of an opioid risk tool may help you identify patients who are at high risk of misuse. There are a number of opioid risk tools. The one commonly recommended in Australia is the Opioid Risk Tool
- B Maximum doses?: Morphine oral modified release 100 mg daily; Oxycodone oral modified release 80 mg daily; burepnorphine transdermal patch 20 micrograms/hr
- An Opioid contract such as the one recommended by the Agency for Clinical Innovation (NSW) may be a useful template to use with people currently taking opioids or requesting them for the first time

## **TABLE 1**

#### Behaviours that may indicate misuse

### Highly predictive behaviours

- Selling prescription medicines
- ▶ Injecting oral formulations
- ▶ Concurrent abuse of alcohol and/or illicit substances
- Multiple unsanctioned dose escalations
- Multiple claims that prescriptions have been lost
- Repeated resistance to change in therapy despite evidence of adverse effects from treatment

#### Less predictive behaviours

- ▶ Abrupt requests for dose escalation
- ▶ Hoarding of medicines during periods of reduced symptoms
- Requesting specific medicines
- Unsanctioned dose escalation
- ▶ Unapproved use of medicine to treat other symptoms

Department of Health. National Prescribing Service Limited. ABN 61082034393.

The Department of Health and Human Services. Protocol for prescribing opioids in Tasmania. 2011. http://www.dhhs.tas.gov.au/\_\_data/assets/pdf\_file/0004/77701/ Protocol\_for\_prescribing\_opioids\_in\_Tasmania.pdf (accessed 4 March 2015).

Expert Group for Analgesics. Therapeutic Guidelines: Analgesic version 6. Melbourne: Therapeutic Guidelines Ltd, 2012.